Infrared Photobiomodulation in Humans With Epilepsy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeth Israel Deaconess Medical Center

About this trial

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This study aims to investigate a new treatment that involves using infra-red light. In animals, this treatment has shown promise as a possible way to reduce seizures, but it has not been tested in humans for this. The investigators are interested to know if it can reduce seizures, and how comfortable it is to be treated with this therapy.

Eligibility criteria

Qualifiers

Drug resistant epilepsy

Age 18 or older

Average seizure rate of at least 2 seizures per month

Accurate seizure diary with at least 3 months recorded

Disqualifiers

Implanted intracranial neurostimulation device (DBS or RNS)

Intracranial shunt

Skin photosensitivity

Cancer on scalp

Trial design

Treatments tested in this trial

  • photobiomodulation

Treatment groups

13 Participants
are divided into 1 treatment group